Core Viewpoint - The company, Dongxing Medical, is terminating its IPO fundraising project for the Zihang Medical Device Component Intelligent Manufacturing and Expansion Project due to fluctuations in downstream market demand, and is delaying the completion date for the Weike Medical Minimally Invasive Surgical New Product Project to December 31, 2027 [1][2][7]. Summary by Sections IPO Fundraising Projects - Dongxing Medical announced the termination of the Zihang Medical Device Component Intelligent Manufacturing and Expansion Project and the extension of the Weike Medical Minimally Invasive Surgical New Product Project's completion date to December 31, 2027 [2][7]. - The company raised a net amount of 1.003 billion yuan from its IPO, which was allocated to three main projects [2][3]. Investment Progress - As of May 2025, Dongxing Medical has utilized 171 million yuan of the raised funds, achieving an overall investment progress of only 25.9% [3]. - The investment progress for the Zihang project is 24.6%, while the Weike project is at 16.97%, and the Medical Surgical Instrument R&D Center project is at 30.5% [3]. Financial Performance - Dongxing Medical has experienced a continuous decline in its net profit excluding non-recurring items for three consecutive years, with an overall decrease of approximately 35.5% [6][9]. - The company's revenue and net profit figures from 2021 to 2024 show a downward trend, with a slight recovery in 2024 [8][9]. Market Conditions - The decision to terminate the Zihang project is attributed to changes in market conditions, including intensified competition and a decrease in customer order demand [7]. - The company faces challenges from price drops due to volume-based procurement policies, which have pressured its performance [7]. Stock Performance - As of June 25, Dongxing Medical's stock price closed at 24.77 yuan per share, representing a nearly 44% decline from its IPO price of 44.09 yuan [10].

Core Viewpoint - The company, Hengguang Co., Ltd., is experiencing a slowdown in the construction progress of its fundraising projects due to the low industry prosperity cycle, leading to a delay in the completion of its 55,000-ton fine chemical new materials production line project from June 30, 2025, to December 31, 2026 [1] Group 1: Project Updates - The 55,000-ton fine chemical new materials production line project includes two sub-projects: a 5,000-ton 2-ethyl anthraquinone production line and a 50,000-ton sodium chlorite production line [2] - The company has completed the technical optimization of the 5,000-ton 2-ethyl anthraquinone production line, but achieving full production will take additional time [2] - Due to the complex market environment and macroeconomic conditions, the company has decided to suspend the investment in the 50,000-ton sodium chlorite production line [2] Group 2: Financial Performance - Since its IPO, Hengguang Co., Ltd. has invested a total of 3.43 billion yuan in its fundraising projects, with an overall investment progress of 60.57% as of May 2025 [1] - The company reported revenues of 933 million yuan, 1.08 billion yuan, 936 million yuan, and 1.235 billion yuan from 2021 to 2024, with net profits of 242 million yuan, 202 million yuan, -37.55 million yuan, and -60.93 million yuan respectively [2] - The company has incurred losses for two consecutive years in 2023 and 2024, totaling approximately 98.48 million yuan [2] Group 3: Reasons for Losses - The company attributes its losses in 2024 to four main factors: low product gross margins, high fixed costs due to increased production capacity, rising energy prices post-market reform, and asset impairment provisions [3] - The gross margin for the company's main business was 8.05% in 2024, a decrease of 1.58 percentage points year-on-year [3] - The gross margins for the chlor-alkali and sulfur chemical product chains were 9.69% and 3.02%, reflecting changes of 3.13 and -12.93 percentage points respectively [3]

晶升股份(SH688478，股价28.44元，市值39.35亿元)上市已超过两年时间。然而，公司一个IPO(首次公 开募股)募投项目却经历了两次地址变更和两次延期，截至去年底累计投入进度仅4.29%。 对此，上交所近期下发问询函，要求晶升股份说明多次变更"半导体晶体生长设备总装测试厂区建设项 目"实施地点、延期实施的原因及合理性。 5月29日，晶升股份回复了上交所问询函。晶升股份表示，该项目延期系受下游应用领域及半导体等行 业短暂调整及供需错配等因素影响。 募投项目两次延期 2023年4月，晶升股份登陆上交所科创板，距今已经超过2年时间。 然而，晶升股份的IPO募投项目"半导体晶体生长设备总装测试厂区建设项目"(以下简称晶体生长设备项 目)却经历了两次延期和两次变更地点。据晶升股份2024年年报，截至去年底，该项目的累计投入进度 仅为4.29%。 晶升股份招股书显示，公司IPO募投项目总计有两个，分别是"总部生产及研发中心建设项目"和"晶体生 长设备项目"，拟投资金额分别约为2.7亿元和2亿元。 按照当时的规划，晶升股份预估"晶体生长设备项目"建设周期为24个月，计划于2022年上半年开始建 设，2022年末 ...

每经记者｜赵李南 每经编辑｜张益铭 5月29日，晶升股份（SH688478，股价28.89元，市值39.97亿元）回复了上交所问询函。 《每日经济新闻》记者注意到，晶升股份上市已经超过2年时间。然而，其募投项目之一却经历了两次地址变更和两次延期，截至去年底累计投入进度仅 4.29%。 然而，晶升股份的募投项目"半导体晶体生长设备总装测试厂区建设项目"（以下简称晶体生长设备项目）却经历了两次延期和两次变更地点。据晶升股份 2024年年报，截至去年底该项目的累计投入进度仅为4.29%。 据晶升股份招股书，其IPO（首次公开募股）募投项目总计有两个，分别是"总部生产及研发中心建设项目"和"晶体生长设备项目"，拟投资金额分别约2.7亿 元和2亿元。 | 序号 | 项目名称 | 投资总额 | 拟投入: | | --- | --- | --- | --- | | | 总部生产及研发 中心建设项目 | 27,365.39 | | | 2 | 半导体晶体生长 设备总装测试厂 | 20,255.00 | | | | 区建设项目 | | | | | 合计 | 47.620.39 | | 图片来源：晶升股份招股书截图 按照当时的规 ...

因此，企业必须提前对募投项目备案流程、变更、特殊备案情形、备案失效、涉及到建设用地和办公用 地等方面进行充分了解，才能做到事半功倍。 为了帮助拟上市企业和中介机构深入理解募投资金备案的监管要求和实操难点， 5月24日晚8点 ，北京 德恒律师事务所合伙人 王贺 律师将为我们直播分享 《 A股上市募集资金备案解析》 ，扫码立即了 解！ IPO募投项目备案是企业上市募集资金的重要步骤，如果备案程序存在问题，那么可能直接影响募投项 目的实施进程，对募集资金的规划与落实形成实质阻碍。 购 课 福 利 直播过程中，购买王贺律师的《A 股上市月月谈》课程，将赠送书 籍:《中国企业境内外上市IPO— ―制度规则透析与实战攻略》 Part 2 总体要求 募投项目主管机构 Part 3 Part 4 项目备案所需提交的材料 一、项目单位基本情况 二、项目名称、建设地点、建设规模、建设内容 三、项目总投资额 四、项目符合产业政策声明 Part 5 备案流程 Part 6 )项目备案有效期 Part 7 页目备案后变更 Part 8 | 部分项目未备案 案例1:不属于固定资产投资项目无需备案 案例2:创新药研发项目不属于项目核准或备 ...

5月16日晚间，北京证券交易所(简称"北交所")上市委员会今年第6次审议会议结果出炉，江苏酉立智能装备股份 有限公司(简称"酉立智能")符合发行条件、上市条件和信息披露要求，成功过会。 上市委员会审议会议向酉立智能提出问询的主要问题包括，业绩真实性和可持续性，研发能力以及股权转让。审 议会议现场相关问题在此前的两轮审核问询中已有所体现。 客户集中度较高，行业发展受政策影响较大 酉立智能于2024年6月申报北交所IPO，公司主营业务为光伏支架核心零部件的研发、生产和销售。 2022年至2024年，酉立智能分别实现营业收入4.33亿元、6.58亿元及7.29亿元；同期扣非归母净利润分别为5226.61 万元、7631.52万元及8921.78万元。酉立智能预计，2025年1-3月实现营业收入2.17亿元至2.37亿元，较2024年同期 预计增长幅度为17.31%至28.13%；预计实现扣除非经常性损益后归属于母公司所有者的净利润为3388.47万元至 3488.47万元，较2024年同期预计增长幅度为23.88%至27.53%。 据招股书信息，酉立智能存在客户集中度较高和单一大客户依赖的风险。报告期内，酉立智能对 ...

每经记者 梁枭 每经编辑 魏官红 原力数字于去年年底披露招股说明书（申报稿，以下简称招股书），闯关北交所IPO（首次公开募股）。原力数字以3D数字内 容制作服务为主业，曾为《博德之门3》《三角洲行动》等知名游戏制作3D动画。 这是原力数字第二次冲刺上市，公司曾于2021年申报创业板IPO。（详见每日经济新闻此前报道《〈哪吒2〉登顶全球动画电影 票房榜！背后特效公司原力数字正闯关北交所：以"代工"业务为主，曾转型原创折戟》） 此次冲刺北交所IPO，原力数字欲募资4.88亿元，拟投入三个项目，其中，"原力数字科技创新产业基地项目"拟投入募资3.64亿 元，该项目总投资额为5.57亿元。综合公开信息以及《每日经济新闻》记者实地探访的结果来看，该项目目前已部分建成并投入 使用。 | | | | 单位:万元 | | --- | --- | --- | --- | | 序号 | 项目名称 | 项目投资总额 | 事集资金拟 投入金额 | | 1 | 原力数字科技创新产业基地项目 | 55,668.61 | 36.431.24 | | 2 | 数字内容创新技术平台建设项目 | 5,920.86 | 5,301.06 | | ...